121 related articles for article (PubMed ID: 36195266)
21. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy.
Wang S; Zhang J; Wang Y; Chen M
Nanomedicine; 2016 Feb; 12(2):411-20. PubMed ID: 26711968
[TBL] [Abstract][Full Text] [Related]
22. Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells.
O'Grady S; Crown J; Duffy MJ
Med Oncol; 2022 Jul; 39(10):142. PubMed ID: 35834073
[TBL] [Abstract][Full Text] [Related]
23. CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma.
Gerardo-Ramírez M; Keggenhoff FL; Giam V; Becker D; Groth M; Hartmann N; Straub BK; Morrison H; Galle PR; Marquardt JU; Herrlich P; Hartmann M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955749
[TBL] [Abstract][Full Text] [Related]
24. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
[TBL] [Abstract][Full Text] [Related]
25. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.
Cheriyan VT; Muthu M; Patel K; Sekhar S; Rajeswaran W; Larsen SD; Polin L; Levi E; Singh M; Rishi AK
Oncotarget; 2016 Nov; 7(45):73370-73388. PubMed ID: 27687593
[TBL] [Abstract][Full Text] [Related]
26. Lineage-specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture.
Liverani C; De Vita A; Spadazzi C; Miserocchi G; Cocchi C; Bongiovanni A; De Lucia A; La Manna F; Fabbri F; Tebaldi M; Amadori D; Tasciotti E; Martinelli G; Mercatali L; Ibrahim T
Mol Oncol; 2022 Feb; 16(4):921-939. PubMed ID: 34109737
[TBL] [Abstract][Full Text] [Related]
27. Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling.
Dunkern TR; Wedemeyer I; Baumgärtner M; Fritz G; Kaina B
DNA Repair (Amst); 2003 Jan; 2(1):49-60. PubMed ID: 12509267
[TBL] [Abstract][Full Text] [Related]
28. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
29. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response.
Lin S; Yu L; Song X; Bi J; Jiang L; Wang Y; He M; Xiao Q; Sun M; Olopade OI; Zhao L; Wei M
Cell Death Dis; 2019 Sep; 10(9):666. PubMed ID: 31511498
[TBL] [Abstract][Full Text] [Related]
30. Doxorubicin-Resistant TNBC Cells Exhibit Rapid Growth with Cancer Stem Cell-like Properties and EMT Phenotype, Which Can Be Transferred to Parental Cells through Autocrine Signaling.
Paramanantham A; Jung EJ; Kim HJ; Jeong BK; Jung JM; Kim GS; Chan HS; Lee WS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830320
[TBL] [Abstract][Full Text] [Related]
31. Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer.
Wijdeven RH; Pang B; van der Zanden SY; Qiao X; Blomen V; Hoogstraat M; Lips EH; Janssen L; Wessels L; Brummelkamp TR; Neefjes J
Cancer Res; 2015 Oct; 75(19):4176-87. PubMed ID: 26260527
[TBL] [Abstract][Full Text] [Related]
32. Dihydrotestosterone Induces Chemo-Resistance of Triple-Negative Breast MDA-MB-231 Cancer Cells Towards Doxorubicin Independent of ABCG2 and miR-328-3p.
Al-Momany B; Hammad H; Ahram M
Curr Mol Pharmacol; 2021; 14(5):860-870. PubMed ID: 34061013
[TBL] [Abstract][Full Text] [Related]
33. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Chewchuk S; Guo B; Parissenti AM
PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
[TBL] [Abstract][Full Text] [Related]
34. Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells.
Tudoran O; Soritau O; Balacescu L; Visan S; Barbos O; Cojocneanu-Petric R; Balacescu O; Berindan-Neagoe I
Mol Cell Biochem; 2015 Nov; 409(1-2):163-76. PubMed ID: 26187676
[TBL] [Abstract][Full Text] [Related]
35. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness.
Shin VY; Chen J; Cheuk IW; Siu MT; Ho CW; Wang X; Jin H; Kwong A
Cell Death Dis; 2019 Mar; 10(4):270. PubMed ID: 30894512
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapeutic Stress Influences Epithelial-Mesenchymal Transition and Stemness in Cancer Stem Cells of Triple-Negative Breast Cancer.
Li X; Strietz J; Bleilevens A; Stickeler E; Maurer J
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936348
[TBL] [Abstract][Full Text] [Related]
37. Study on the Mechanism of Cell Cycle Checkpoint Kinase 2 (CHEK2) Gene Dysfunction in Chemotherapeutic Drug Resistance of Triple Negative Breast Cancer Cells.
Luo L; Gao W; Wang J; Wang D; Peng X; Jia Z; Jiang Y; Li G; Tang D; Wang Y
Med Sci Monit; 2018 May; 24():3176-3183. PubMed ID: 29761796
[TBL] [Abstract][Full Text] [Related]
38. The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer.
Raza U; Saatci Ö; Uhlmann S; Ansari SA; Eyüpoğlu E; Yurdusev E; Mutlu M; Ersan PG; Altundağ MK; Zhang JD; Doğan HT; Güler G; Şahin Ö
Oncotarget; 2016 Aug; 7(31):49859-49877. PubMed ID: 27409664
[TBL] [Abstract][Full Text] [Related]
39. BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells.
Das CK; Linder B; Bonn F; Rothweiler F; Dikic I; Michaelis M; Cinatl J; Mandal M; Kögel D
Neoplasia; 2018 Mar; 20(3):263-279. PubMed ID: 29462756
[TBL] [Abstract][Full Text] [Related]
40. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
